PathGroup announces expansion of SmartGenomics offering to include profiling of hematologic malignancies

March 20, 2014

PathGroup, a provider of pathology services, has announced the launch of the SmartGenomics Heme Profile, which provides genomic profiling and information for patients who have been unsuccessful on repeated therapy for the group of cancers that include leukemias, lymphomas and myeloproliferative/myelodysplastic diseases. The newly launched offering is based on collaboration between PathGroup, GenoSpace, and the IP & Science business of Thomson Reuters.

The SmartGenomics Heme Profile includes next-generation DNA sequencing of 77 clinically actionable genes mutated in hematolymphoid cancers and is complemented by array-based comparative genomic hybridization for whole genome level identification of chromosomal copy number changes and loss of heterozygosity. Results provide the treating oncologist with prognostic, predictive, and therapeutic information, as well as available clinical trial options.

Prevalence estimates from the National Cancer Institute’s Surveillance Epidemiology and End Results Cancer Statistics Review indicate that there are approximately one million individuals in the country living with a diagnosis of Hodgkin disease, leukemia, multiple myeloma, or non-Hodgkin lymphoma, in addition to myeloproliferative/myelodysplastic diseases. Up to 50% of these diseases ultimately are refractory to treatment.

“When PathGroup committed to providing genomic profiling to community oncologists and researchers, we understood early in the development process that independent interrogation of cancers originating in the bone marrow, blood, and lymphatic system would be an imperative complement to any exploration of solid tumors,” states Ben Davis, MD, Chairman, President and CEO of PathGroup. “As was the case when we released SmartGenomics for solid tumors, we will continue to rely on the exceptional data aggregation and reporting that GenoSpace and Thomson Reuters afford.” Learn about services provided to the clinical laboratory by PathGroup.

Read more